Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ADMA Biologics ( (ADMA) ) has issued an update.
On June 4, 2025, ADMA Biologics, Inc. held its Annual Meeting of Stockholders, where key decisions were made, including the election of two Class III directors, ratification of KPMG LLP as the independent public accounting firm for 2025, approval of executive compensation, and setting the frequency of future advisory votes on executive pay to annually. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (ADMA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.
Spark’s Take on ADMA Stock
According to Spark, TipRanks’ AI Analyst, ADMA is a Outperform.
ADMA Biologics’ strong financial performance and optimistic earnings call are the most significant factors driving a positive stock score. Technical stability and a reasonable valuation further contribute to the stock’s appeal, while the absence of a dividend is typical for its industry.
To see Spark’s full report on ADMA stock, click here.
More about ADMA Biologics
ADMA Biologics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.
Average Trading Volume: 3,580,680
Technical Sentiment Signal: Buy
Current Market Cap: $4.88B
Learn more about ADMA stock on TipRanks’ Stock Analysis page.